GlassScriptPhysician profile
Saritha C Thumma
NPI 1952445223
$5,116.35
in general payments reported to CMS, 2019-2025
42 companies · $3,439 in 2025
The $3,439 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.79 · 2022: $14.83 · 2023: $111 · 2024: $1,527 · 2025: $3,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,562 · Long Term Medical Supply Or Device Loan: $1,363 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,561.62 |
| Long Term Medical Supply Or Device Loan | $1,363.06 |
| Education | $152.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,765.76 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $412.86 | 2024-2025 | Imfinzi, Enhertu, Calquence |
| Tempus Ai, INC | $221.76 | 2024 | |
| Pfizer INC. | $192.27 | 2025 | |
| Merck Sharp & Dohme LLC | $188.44 | 2024-2025 | Keytruda, Lynparza, Reblozyl |
| Abbvie INC. | $170.39 | 2024-2025 | |
| Celgene Corporation | $141.31 | 2022-2025 | Reblozyl, Breyanzi |
| E.R. Squibb & Sons, L.L.C. | $139.54 | 2023-2025 | Opdualag, Opdivo |
| Glaxosmithkline, LLC. | $114.28 | 2025 | Zejula, Jemperli |
| Janssen Biotech, INC. | $111.67 | 2024-2025 | Erleada, Talvey, Tecvayli |
| Incyte Corporation | $109.96 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $97.96 | 2024-2025 | Verzenio |
| Genentech USA, INC. | $92.71 | 2021-2025 | Itovebi, Tecentriq, Tecentriq Hybreza |
| Array Biopharma INC | $89.03 | 2024-2025 | Braftovi, Lorbrena, Xalkori |
| Dendreon Pharmaceuticals LLC | $83.00 | 2023-2025 | Provenge |
Show all 40 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saritha Thumma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.